The self-evolving pharmaceutical company.
EvoPharma combines AI-driven discovery, global intelligence, CRO synthesis, external validation, and open earn-in ownership to build medicines differently.
The future owners have not been chosen.
10% founder ownership is locked. Exactly 90% ownership remains open to builders who create measurable value.
Evolving Science. Evolving Ownership. Evolving Medicine.
EvoPharma is designed as a living pharmaceutical organization where the best contributors can emerge from anywhere, solve critical problems, earn ownership, and shape the company through impact.
Evolving science
AI-driven discovery, computational design, CRO synthesis, biological validation, and continuous optimization.
Fully outsourced execution
No unnecessary laboratories or fixed infrastructure. Capital is deployed directly into experiments and knowledge creation.
Evolving ownership
Ownership is earned through verified scientific, technical, operational, legal, financial, and strategic contribution.
Mission
To reinvent pharmaceutical innovation by creating a self-evolving, AI-enabled, globally distributed company where the world's best minds collaborate to create transformative medicines and earn ownership through impact.
Vision
A future where pharmaceutical companies are not defined by buildings, borders, or predetermined organizations, but by evolving networks of global intelligence dedicated to creating transformative medicines.
Therapeutic portfolio
Aging & longevity
Therapies targeting biological mechanisms of aging and age-associated decline.
Oncology
Next-generation cancer therapeutics using AI-guided discovery and outsourced validation.
Cardiometabolic medicine
PCSK9 cholesterol control and GLP-1 metabolic health programs.